Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Clinical, Sonographic, and Pathological Characteristics of RAS-Positive Versus BRAF-Positive Thyroid Carcinoma.

Kakarmath S, Heller HT, Alexander CA, Cibas ES, Krane JF, Barletta JA, Lindeman NI, Frates MC, Benson CB, Gawande AA, Cho NL, Nehs M, Moore FD, Marqusee E, Kim MI, Larsen PR, Kwong N, Angell TE, Alexander EK.

J Clin Endocrinol Metab. 2016 Dec;101(12):4938-4944.

PMID:
27689252
2.

Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma.

Makhlouf AM, Chitikova Z, Pusztaszeri M, Berczy M, Delucinge-Vivier C, Triponez F, Meyer P, Philippe J, Dibner C.

Oncotarget. 2016 Jul 19;7(29):45776-45788. doi: 10.18632/oncotarget.10166.

3.

Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments.

Mohamed AF, González JM, Fairchild A.

J Thyroid Res. 2015;2015:438235. doi: 10.1155/2015/438235.

4.

Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules.

Zhang YZ, Xu T, Cui D, Li X, Yao Q, Gong HY, Liu XY, Chen HH, Jiang L, Ye XH, Zhang ZH, Shen MP, Duan Y, Yang T, Wu XH.

Sci Rep. 2015 Nov 24;5:16927. doi: 10.1038/srep16927.

5.

BRAF Testing in Multifocal Papillary Thyroid Carcinoma.

Kimbrell HZ, Sholl AB, Ratnayaka S, Japa S, Lacey M, Carpio G, Bhatia P, Kandil E.

Biomed Res Int. 2015;2015:486391. doi: 10.1155/2015/486391.

6.

The variable phenotype and low-risk nature of RAS-positive thyroid nodules.

Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, Benson CB, Cibas ES, Barletta JA, Krane JF, Ruan DT, Cho NL, Gawande AA, Moore FD Jr, Alexander EK.

BMC Med. 2015 Aug 7;13:184. doi: 10.1186/s12916-015-0419-z.

7.

The Treatment of Well-Differentiated Thyroid Carcinoma.

Paschke R, Lincke T, Müller SP, Kreissl MC, Dralle H, Fassnacht M.

Dtsch Arztebl Int. 2015 Jun 26;112(26):452-8. doi: 10.3238/arztebl.2015.0452. Review.

8.

BRAF gene: From human cancers to developmental syndromes.

Hussain MR, Baig M, Mohamoud HS, Ulhaq Z, Hoessli DC, Khogeer GS, Al-Sayed RR, Al-Aama JY.

Saudi J Biol Sci. 2015 Jul;22(4):359-73. doi: 10.1016/j.sjbs.2014.10.002. Review.

9.

Mouse models of thyroid cancer: A 2015 update.

Kirschner LS, Qamri Z, Kari S, Ashtekar A.

Mol Cell Endocrinol. 2016 Feb 5;421:18-27. doi: 10.1016/j.mce.2015.06.029. Review.

10.

American Thyroid Association Statement on Surgical Application of Molecular Profiling for Thyroid Nodules: Current Impact on Perioperative Decision Making.

Ferris RL, Baloch Z, Bernet V, Chen A, Fahey TJ 3rd, Ganly I, Hodak SP, Kebebew E, Patel KN, Shaha A, Steward DL, Tufano RP, Wiseman SM, Carty SE; American Thyroid Association Surgical Affairs Committee..

Thyroid. 2015 Jul;25(7):760-8. doi: 10.1089/thy.2014.0502. Review.

11.

Multicentric occurrence of multiple papillary thyroid carcinomas--HUMARA and BRAF mutation analysis.

Nakazawa T, Kondo T, Tahara I, Kasai K, Inoue T, Oishi N, Mochizuki K, Kubota T, Katoh R.

Cancer Med. 2015 Aug;4(8):1272-80. doi: 10.1002/cam4.466.

12.

Metastatic mesothelioma to the thyroid.

Rao SN, Swami A, Khan A, Toke M, Whalen G, Fischer A, Torres MS.

Cytojournal. 2014 May 22;11:11. doi: 10.4103/1742-6413.132984.

13.

Molecular diagnostics of fine needle aspiration for the presurgical screening of thyroid nodules.

Fallahi P, Giannini R, Miccoli P, Antonelli A, Basolo F.

Curr Genomics. 2014 Jun;15(3):171-7. doi: 10.2174/1389202915999140404100347.

14.

Utility of molecular tests in cytopathology.

Somoza AD, Aly FZ.

Cytojournal. 2014 Mar 20;11:5. doi: 10.4103/1742-6413.129183. Review.

15.

Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China.

Guo HQ, Zhao H, Zhang ZH, Zhu YL, Xiao T, Pan QJ.

Dis Markers. 2014;2014:912182. doi: 10.1155/2014/912182.

16.

Follicular adenomas exhibit a unique metabolic profile. ¹H NMR studies of thyroid lesions.

Deja S, Dawiskiba T, Balcerzak W, Orczyk-Pawiłowicz M, Głód M, Pawełka D, Młynarz P.

PLoS One. 2013 Dec 23;8(12):e84637. doi: 10.1371/journal.pone.0084637.

17.

Organ Specific Tumor Markers: What's New?

Vaidyanathan K, Vasudevan DM.

Indian J Clin Biochem. 2012 Apr;27(2):110-20. doi: 10.1007/s12291-011-0173-8.

19.

DNA copy number variations characterize benign and malignant thyroid tumors.

Liu Y, Cope L, Sun W, Wang Y, Prasad N, Sangenario L, Talbot K, Somervell H, Westra W, Bishop J, Califano J, Zeiger M, Umbricht C.

J Clin Endocrinol Metab. 2013 Mar;98(3):E558-66. doi: 10.1210/jc.2012-3113.

20.

Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.

Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH.

Transl Oncol. 2012 Dec;5(6):430-6.

Items per page

Supplemental Content

Support Center